Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex

Human Molecular Genetics

Volumn 20, Issue 23, 2011, Pages 4597-4604

  Anderl, Stefanie ^a   Freeland, Megan ^a   Kwiatkowski, David J ^a   Goto, June ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CELL COUNT; CONTROLLED STUDY; DISEASE MODEL; FEMALE; FETOPLACENTAL UNIT; GENE LOSS; GROWTH RETARDATION; LETHALITY; MALE; MOUSE; NEURAL STEM CELL; NEWBORN; NEWBORN DEATH; NEWBORN MORTALITY; NONHUMAN; POSTNATAL CARE; PRENATAL CARE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPONTANEOUS ABORTION; TUBEROUS SCLEROSIS;

ANIMALS; ANIMALS, NEWBORN; BRAIN; CELL COUNT; CELL SIZE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INTEGRASES; INTERMEDIATE FILAMENT PROTEINS; MICE; NERVE TISSUE PROTEINS; NEURONS; PHENOTYPE; PREGNANCY; SIGNAL TRANSDUCTION; SIROLIMUS; SURVIVAL ANALYSIS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS;

MUS; NES;

EID: 81055153389     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr393     Document Type: Article

References (31)

1. Jozwiak, J., Jozwiak, S. and Wlodarski, P. (2008) Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol., 9, 73-79.
2. Kwiatkowski, D.J., Thiele, E.A. and Whittemore, V.H. (eds). (2010) Tuberous Sclerosis Complex: Genes, Clinical Features, and Therapeutics. Wiley-Blackwell, Weinheim, Germany.
3. Holmes, G.L. and Stafstrom, C.E., Tuberous Sclerosis Study Group (2007) Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia, 48, 617-630.
4. Doherty, C., Goh, S., Poussaint, T.Y., Erdag, N. and Thiele, E.A. (2005) Prognostic significance of tuber count and location in tuberous sclerosis complex. J. Child Neurol., 20, 837-841.
5. Thiele, E.A. (2004) Managing epilepsy in tuberous sclerosis complex. J. Child Neurol., 19, 680-686.
6. Park, S.H., Pepkowitz, S.H., Kerfoot, C., DeRosa, M.J., Poukens, V., Wienecke, R., DeClue, J.E. and Vinters, H.V. (1997) Tuberous sclerosis in a 20-week gestation fetus: immunohistochemical study. Acta Neuropathol., 94, 180-186.
7. Bordarier, C., Lellouchtubiana, A. and Robain, O. (1994) Cardiac rhabdomyoma and tuberous sclerosis in 3 fetuses-a neuropathological study. Brain Dev., 16, 467-471.
8. Qin, W., Kozlowski, P., Taillon, B.E., Bouffard, P., Holmes, A.J., Janne, P., Camposano, S., Thiele, E., Franz, D. and Kwiatkowski, D.J. (2010) Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex. Hum. Genet., 127, 573-582.
9. Crino, P.B., Aronica, E., Baltuch, G. and Nathanson, K.L. (2010) Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology, 74, 1716-1723.
10. Sabatini, D.M. (2006) mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer., 6, 729-734.
11. Guertin, D.A., Stevens, D.M., Thoreen, C.C., Burds, A.A., Kalaany, N.Y., Moffat, J., Brown, M., Fitzgerald, K.J. and Sabatini, D.M. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKC alpha but not S6K1. Dev. Cell., 11, 859-871.
12. Huang, J.X., Wu, S.L., Wu, C.L. and Manning, B.D. (2009) Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res., 69, 6107-6114.
13. Fingar, D.C. and Blenis, J. (2004) Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene, 23, 3151-3171.
14. Laplante, M. and Sabatini, D.M. (2009) An emerging role of mTOR in lipid biosynthesis. Curr. Biol., 19, 1046-1052.
15. Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W.D., Kwiatkowski, D.J., Ramesh, V. and Silva, A.J. (2008) Reversal of learning deficits in a Tsc2(+/-) mouse model of tuberous sclerosis. Nat. Med., 14, 843-848.
16. Zeng, L.H., Xu, L., Gutmann, D.H. and Wong, M. (2008) Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann. Neurol., 63, 444-453.
17. Meikle, L., Pollizzi, K., Egnor, A., Kramvis, I., Lane, H., Sahin, M. and Kwiatkowski, D.J. (2008) Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J. Neurosci., 28, 5422-5432.
18. Krueger, D.A., Care, M.M., Holland, K., Agricola, K., Tudor, C., Mangeshkar, P., Wilson, K.A., Byars, A., Sahmoud, T. and Franz, D.N. (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med., 363, 1801-1811.
19. Franz, D.N., Leonard, J., Tudor, C., Chuck, G., Care, M., Sethuraman, G., Dinopoulos, A., Thomas, G. and Crone, K.R. (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol., 59, 490-498.
20. McKay, D.B. and Josephson, M.A. (2008) Pregnancy after kidney transplantation. Clin. J. Am. Soc. Nephrol., 3, 117-125.
21. Sifontis, N.M., Coscia, L.A., Constantinescu, S., Lavelanet, A.F., Moritz, M.J. and Armenti, V.T. (2006) Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation, 82, 1698-1702.
22. Chu, S.H., Liu, K.L., Chiang, Y.J., Wang, H.H. and Lai, P.C. (2008) Sirolimus used during pregnancy in a living related renal transplant recipient: a case report. Transplant. Proc., 40, 2446-2448.
23. Tronche, F., Kellendonk, C., Kretz, O., Gass, P., Anlag, K., Orban, P.C., Bock, R., Klein, R. and Schutz, G. (1999) Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat. Genet., 23, 99-103.
24. Narayanan, S.P., Flores, A.I., Wang, F. and Macklin, W.B. (2009) Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J. Neurosci., 29, 6860-6870.
25. Tyler, W.A., Gangoli, N., Gokina, P., Kim, H.A., Covey, M., Levison, S.W. and Wood, T.L. (2009) Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J. Neurosci., 29, 6367-6378.
26. Onda, H., Crino, P.B., Zhang, H.B., Murphey, R.D., Rastelli, L., Gould Rothberg, B.E. and Kwiatkowski, D.J. (2002) Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol. Cel. Neurosci., 21, 561-574.
27. Bissler, J.J., McCormack, F.X., Young, L.R., Elwing, J.M., Chuck, G., Leonard, J.M., Schmithorst, V.J., Laor, T., Brody, A.S., Bean, J. et al. (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med., 358, 140-151.
28. McCormack, F.X., Inoue, Y., Moss, J., Singer, L.G., Strange, C., Nakata, K., Barker, A.F., Chapman, J.T., Brantly, M.L., Stocks, J.M. et al. (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N. Engl. J. Med., 364, 1595-1606.
29. Pollizzi, K., Malinowska-Kolodziej, I., Stumm, M., Lane, H. and Kwiatkowski, D.J. (2009) Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol. Cancer., 8, 38.
30. Way, S.W., McKenna, J., Mietzsch, U., Reith, R.M., Wu, H.C. and Gambello, M.J. (2009) Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Hum. Mol. Genet., 18, 1252-1265.
31. Coscia, L.A. and Armenti, V.T. (2010) Transplantation: pregnancy outcomes in kidney recipients: more data are needed. Nat. Rev. Nephrol., 6, 131-132.